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Abstract
AIM
To study exercise capacity and determinants of early peak 
oxygen consumption (VO2peak) in a cohort of de novo heart 
transplant (HTx) recipients. 
METHODS
To determine possible central (chronotropic responses, 
cardiopulmonary and hemodynamic function) and peri-
pheral factors (muscular exercise capacity and body 
composition) predictive of VO2peak, a number of different 
measurements and tests were performed, as follows: 
Cardiopulmonary exercise testing (CPET) was performed 
mean 11 wk after surgery in 81 HTx recipients > 18 years 
and was measured with breath by breath gas exchange 
on a treadmill or bicycle ergometer. Metabolic/respiratory 
measures include VO2peak and VE/VCO2 slope. Additional 
measures included muscle strength testing, bioelectrical 
impedance analysis, echocardiography, blood sampling 
and health-related quality of life. Based on the VO2peak (mL/
kg per minute) median value, the study population was 
divided into two groups defined as a low-capacity group 
and a high-capacity group. Potential predictors were 
analyzed using multiple regression analysis with VO2peak 
(L/min) as the dependent variable.
RESULTS
The mean ± standard deviation (SD) age of the total 
study population was 49 ± 13 years, and 73% were 
men. This de novo HTx cohort demonstrated a median 
VO2peak level of 19.4 mL/kg per min at 11 ± 1.8 wk post-
HTx. As compared with the high-capacity group, the 
low-capacity group exercised for a shorter time, had 
lower maximal ventilation, O2 pulse, peak heart rate and 
heart rate reserve, while the VE/VCO2 slope was higher. 
The low-capacity group had less muscle strength and 
muscular exercise capacity in comparison with the high-
capacity group. In order of importance, O2 pulse, heart 
rate reserve, muscular exercise capacity, body mass 
index, gender and age accounted for 84% of the variance 
in VO2peak (L/min). There were no minor or major serious 
adverse events during the CPET. 
CONCLUSION
Although there is great individual variance among de 
novo HTx recipients, early VO2peak measures appear to be 
influenced by both central and peripheral factors.
Key words: Cardiopulmonary exercise testing; Early 
VO2peak; De novo  heart transplant; Health related quality of 
life; Muscle strength
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This de novo  heart transplant (HTx) cohort de-
monstrated a median peak oxygen consumption (VO2peak) 
level of 19.4 mL/kg per min at 11 ± 1.8 wk post-HTx, 
which is comparable to what is shown in maintenance 
HTx recipients. VO2peak in this study was determined 
by both central and peripheral factors. The strongest 
predictors were O2 pulse, heart rate reserve and muscular 
exercise capacity. Maximal exercise testing provides 
valuable information for clinical use and future prognosis 
and can be safely performed as early as 11 wk post-HTx.
Rolid K, Andreassen AK, Yardley M, Bjørkelund E, Karason K, 
Wigh JP, Dall CH, Gustafsson F, Gullestad L, Nytrøen K. Clinical 
features and determinants of VO2peak in de novo heart transplant 
recipients. World J Transplant 2018; 8(5): 188-197  Available 
from: URL: http://www.wjgnet.com/2220-3230/full/v8/i5/188.
htm  DOI: http://dx.doi.org/10.5500/wjt.v8.i5.188
INTRODUCTION
Cardiac rehabilitation, including exercise training to im­
prove exercise capacity and health­related quality of life 
(HRQoL) is recommended after heart transplant (HTx)[1], 
but there are no clear and specific guidelines for how, 
how often or at what intensity exercise training should be 
performed. 
Exercise capacity is often severely reduced shortly 
after HTx with peak oxygen consumption (VO2peak) levels 
reported to be between 9.2 and 19.7 mL/kg per min[2­12]. 
However, early measurement of VO2peak is not routine in 
most centers. VO2peak is the gold standard to objectively 
assess functional limitation and give an assessment of 
the integrative physiology involving cardiovascular, pul­
monary, muscular, cellular and oxidative systems[13,14]. It 
has also been reported that VO2peak is a strong predictor 
for survival in HTx recipients[15,16]. In studies of main­
tenance HTx patients, VO2peak seems to be determined 
by both central (chronotropic incompetence, reduced 
stroke volume and cardiac output, impaired systolic and 
diastolic function, pulmonary dysfunction) and peripheral 
factors (diminished skeletal muscular capacity)[1,17­19]. 
Other factors, like donor characteristics, diagnosis and 
deconditioning before transplantation may also be 
associated with reduced exercise capacity after HTx[18]. 
However, we have recently reported that the most 
important variables predicting VO2peak in maintenance 
HTx patients are mostly of peripheral origin[20,21]. In de 
novo HTx patients, only two studies exist (n = 43[6] 
and n = 24[12]), which report limiting factors for VO2peak. 
These studies indicate that both central and peripheral 
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factors could be involved in the early phase, but the 
knowledge is scarce and thus, a better understanding 
of factors that are associated with peak exercise shortly 
after HTx could guide clinicians and physiotherapist 
for more individualized therapy and specific exercise 
recommendations.
We hypothesized that both central and peripheral 
factors are associated with reduced exercise capacity 
in de novo HTx recipients. In the present study, we 
performed cardiopulmonary exercise testing (CPET) in a 
cohort of de novo HTx patients with the aim to determine 
clinical, hemodynamic and peripheral factors that 
contribute to the reduced exercise capacity.
MATERIALS AND METHODS
Patients and settings
This study was conducted in three centers in Scandinavia 
(Oslo, Gothenburg and Copenhagen). Altogether, 155 de 
novo HTx patients were assessed for eligibility. Of these, 
72 were excluded for various reasons: did not meet 
inclusion criteria (cognitive issues, physical disabilities, 
medical complications, language barriers, contagion, no 
physical therapist available) (n = 43); were not motivated 
(n = 15); logistic reasons (n = 14). In addition, two were 
excluded after they had given their consent, one due 
to medical complications and one withdrawal. A total of 
81 patients underwent CPET. The study was approved 
by the South­East Regional Committee for medical and 
health research ethics in Norway and the Committee 
for medical and health research ethics in Sweden and 
Denmark. The study was conducted in accordance with 
the recommendations in the Helsinki Declaration.
The current study is based on the baseline data from 
an ongoing randomized controlled trial (RCT): The High­
intensity Interval Training in de novo heart Transplant 
recipients in Scandinavia (HITTS) study. The design and 
rationale of this study is described elsewhere[22]. In short, 
the RCT compares the effect of a 9­mo long two­armed 
intervention: High­intensity interval training versus mo­
derate intensity continuous training. 
Inclusion criteria 
The inclusion criteria were: Clinically stable HTx recipients 
approximately 8­12 wk after HTx; Age > 18 years; Both 
sexes; Receiving immunosuppressive therapy according 
to local protocols; Patient willing and able to give written 
informed consent for study participation, and motivated 
to participate in the study for nine months. 
Measurements
The primary endpoint, VO2peak, was measured on a 
treadmill or a bicycle ergometer applying an indivi­
dualized protocol with an incremental workload until 
exhaustion[23]. The Norwegian populations were tested 
on a treadmill, except for four subjects, who could not 
comply and were tested on a bicycle  ergometer. All 
patients in Sweden and Denmark were tested on a 
bicycle, which is the customary form for exercise testing 
in these countries. The variables from the CPET have 
been described previously[22]. Common heart rate (HR) 
variables and abbreviations used in this study were: 
Peak heart rate (HRpeak); Percentage of age­predicted 
maximum HR (% HRmax) = [(HRpeak/220 ­ age) × 100]; 
Chronotropic response index (CRI) = (HRpeak ­HRrest)/(220 
­ age/HRrest); Heart rate reserve (HRreserve ) = HRpeak ­ 
HRrest; HRrecovery  (difference between HRpeak and HR after 
30 s, 1, 2, 3 and 4 min). 
Secondary endpoints
Potential variables influencing VO2peak, such as lung 
function, maximum muscle strength and muscular 
exercise capacity, bioelectrical impedance analysis, echo­
cardiography, blood samples and HRQoL were measured.
Lung function
Different lung function variables were measured in re­
lation to the CPET, both at rest and during exercise. 
Spirometry was performed at rest before CPET: Peak 
expiratory flow (PEF), forced expiratory volume at 1 
min (FEV1), forced vital capacity (FVC) during exercise, 
maximum ventilation (Vmax) and ventilatory efficiency 
(VE/VCO2)[14] were calculated.
Muscle strength and muscular exercise capacity 
Muscle strength and muscular exercise capacity in the 
quadriceps and hamstring muscle groups were measured 
isokinetically. Five repetitions at an angular velocity of 
60°/s were performed when measuring muscle maximal 
strength. For the muscular exercise capacity, 30 isokinetic 
contractions at 240°/s were performed. In the analyses, 
we used the bilateral sum of m. quadriceps and m. ham­
strings[20,22].  
Bioelectrical impedance analysis 
Bioelectrical impedance is a simple and fairly valid 
method to measure body composition[24].  In this study, 
the Tanita (Tanita, Arlington Heights, IL, United States) 
system was used to measure body fat, body water, 
muscle mass, bone mass, visceral fat, metabolic age and 
basal metabolic rate. 
Echocardiography 
Standard Doppler­echocardiography was performed by 
experienced technicians and assessed by cardiologists to 
determine myocardial size and function.
Biochemistry 
All patients underwent blood sampling in the morning in 
a fasting state. Two EDTA tubes were collected, inverted 
ten times and immediately placed on ice. Samples were 
centrifuged within 20 min. Plasma was transferred into 
four vials and frozen at ­80 ℃. One serum tube was 
collected and placed in room temperature for 60 to 120 
min for coagulation before centrifugation. The sample 
was then transferred into two vials and frozen at ­80 ℃. 
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group­wise in Tables 1 and 2. 
Compared to the high­capacity group, the low­capa­
city group was characterized by a higher body mass 
index (BMI) and a higher fat content, they were more 
often ex­smokers, had lower PCS score, had less muscle 
strength and muscular exercise capacity, had lower FEV1, 
FVC and ejection fraction (EF) as measured by echo­
cardiography. The low­capacity group more often used 
beta blockers and less mycophenolate, had higher NT­
proBNP, hs­TnT, triglycerides and lower hemoglobin (Hgb). 
Duration of heart failure before HTx, primary diagnosis, 
donor age, ischemic time, rejection scores, MCS score 
and HADS depression score were similar between the 
two groups (Table 1). 
Exercise variables
Exercise variables are shown in Table 2. As compared 
with the high­capacity group, the low­capacity group 
exercised for a shorter time, had lower maximal venti­
lation, O2 pulse, HRpeak and HRreserve, while VE/VCO2 slope 
was higher (Table 2). The respiratory exchange ratio 
(RER), rated perceived exertion (RPE) and blood pressure 
responses were similar between the groups (Table 2). 
Predictors of VO2peak 
Univariate predictors of VO2peak are shown in Tables 1 and 
2. There were strong correlations (P < 0.001) between 
VO2peak and HRreserve, O2 pulse and muscular exercise 
capacity (Figures 1­3). In multiple regression analyses, O2 
pulse, HRreserve, muscular exercise capacity, BMI, gender 
and age accounted for 84% of the variance in VO2peak 
(L/min). Only O2 pulse, HRreserve and muscular exercise 
capacity were important determinants in the final model 
(P < 0.001, P < 0.001 and P < 0.015, respectively). 
Other potential predictors were also analyzed in the 
multiple regression analyses, but these did not reach 
statistical significance. VO2peak (L/min) was chosen as the 
dependent variable in order to be able to adjust for and 
see the impact of age, gender and BMI directly, as the 
VO2peak (mL/kg per min) variable is already weight­based. 
Safety
All measurements performed in this study, including 
the CPET and muscle strength testing, were completed 
without any minor or serious adverse events. 
DISCUSSION
The main findings in this study were that de novo HTx 
patients display reduced exercise capacity compared 
with a general population: The reference population 
in ACSM[27] and Astrand[28], and that maximal exercise 
capacity was determined by both central (O2 pulse and 
HRreserve) and peripheral factors (muscular exercise capa­
city) (Table 3 and Figures 1­3). Furthermore, CPET can 
be safely performed as early as an average of 11 wk 
after HTx and is a valuable basis for individual tailoring of 
the further rehabilitation program.
Plasma concentrations of N­terminal pro brain na­
triuretic peptide (NT­proBNP) was determined using an 
electrochemiluminescence immunoassay on a Modular 
platform (Roche Diagnostica, Basel, Switzerland), high 
sensitive C­reactive protein (hs­CRP) levels using a 
particle­enhanced, high­sensitive immunoturbidimetric 
assay (hsCRP, Tina­Quant CRP Gen.3), and high­sensitive 
troponin T (hs­TnT) was measured by electrochemi­
luminescence immunoassay (hsTnT, Elecsys Troponin T 
high sensitive, Roche Diagnostics).
HRQoL and symptoms of anxiety and depression 
HRQoL was measured with the generic questionnaire 
short form­36, version 2 (SF­36v2)[25]. The results were 
transformed into norm­based scores on a standardized 
scale with a mean of 50 and a standard deviation (SD) 
of 10[25]. Subscales were aggregated into two sum­
scores; physical component summary (PCS) and mental 
component summary (MCS). Symptoms of anxiety and 
depression were measured with the Hospital Anxiety 
and Depression Scale (HADS)[26]. The values were dicho­
tomized using a cut­off score ≥ 8, which was considered 
to represent symptoms of depression or anxiety.
Statistical analysis 
All data were analyzed using IBM SPSS, version 23 
and version 25.0 (IBM corporation, United States). 
Continuous data are expressed as mean ± SD or median 
first quartile (Q1), third quartile (Q3), and categorical 
data are presented as percentages. Patients were divided 
by the median VO2peak (mL/kg per min) value into a low­
capacity group (≤ 19.4) and a high­capacity group (> 
19.4). Between­group comparisons were performed 
using two independent samples t or Mann Whitney 
U test. χ 2 or F were used for categorical data, where 
appropriate. Bivariate relationships were explored and 
univariate regression analyses were performed with po­
tential predictors (Tables 1 and 2). To identify the degree 
of association with VO2peak, all relevant variables with P 
< 0.05 and other potential variables from the univariate 
analyses of linear regression were selected for further 
multiple regression analyses. VO2peak (L/min), adjusted for 
age, sex and BMI, was used as the dependent variable. 
The final model was built using a series of multiple 
regression analyses with the enter method (Table 3). 
Assumptions were checked for normality and linearity. 
RESULTS
Clinical characteristics 
The mean ± SD age of the total study population was 
49 ± 13 years, and 73% were men. Patients were on 
average 11.1 ± 1.8 wk after HTx. The mean VO2peak was 
20.4 mL/kg per min, which is 56% of expected compared 
to the reference values described in the 9th edition of the 
American College of Sports Medicine’s (ACSM) guidelines 
for exercise testing and exercise prescription[27]. Further 
demographic and clinical characteristics are presented 
Rolid K et al . Early VO2peak in de novo  HTx recipients
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6N = 55-81 Total Low-capacity group 
(n  = 41)
VO2peak ≤ 
19.4 mL/kg per min
High-capacity group 
(n  = 40)
VO2peak > 
19.4 mL/kg per min
t 
(P -value) 
Univariate regression 
Standardized coefficient Beta 
[95%CI], P
VO2peak (L/min)
7R2
Clinical characteristics
Sex (% men) 73% 66 80    0.1521        -0.45 [-0.61, -0.23], < 0.001 0.2
Age (yr)   49 ± 13     51 ± 11   46 ± 15 0.08  -0.19 [-0.01, -0.001], 0.093 0.04
Body mass index 25.3 ± 3.7   26.3 ± 3.4 24.2 ± 3.8 0.01    0.28 [0.007, 0.056], 0.013 0.08
Body fat (%) 25.1 ± 8.7   29.0 ± 8.3 21.0 ± 7.1 <0.001  -0.34 [-0.03, -0.006], 0.003 0.11
Donor age (yr) 34 (24, 49) 37 (27, 48) 33 (23, 52)    0.8252   0.09 [-0.004, 0.009], 0.447 0.01
Ischemic time (min) 210 (95, 237) 215 (99, 249) 185 (87, 227)    0.0722  -0.01[-0.001, 0.001], 0.938 8.2-5
Weeks after HTx    11 ± 1.8 11.3 ± 2 10.9 ± 1.5   0.307   -0.001 [-0.05, 0.05], 0.990 2.0-5
Duration of HF prior to HTx (yr)  4 (1.5, 10) 4 (1.5, 10.5) 4 (1.0, 9.3)    0.7182     -0.05 [-0.02, 0.01], 0.681 0.002
Time on HTx waiting list (d)                 75 (24, 193) 96 (29, 227) 47 (12, 131) 0.062  -0.14 [-0.001, 1.5-4], 0.202 0.02
Rejections grade 1-2 (% yes) 45 48 43    0.6531       0.09 [-0.11, 0.27], 0.408 0.01
VO2peak preHTx  (mL/kg per min)  11.6 ± 3.3 11.1 ± 3 12.1 ± 3.5   0.248   0.03 [-0.032, 0.039], 0.826 0.001
LVAD (% yes) 15 22 8    0.0671   -0.14 [-0.43, 0.097], 0.211 0.02
Preoperative IABP/ECMO (% yes) 16 15 18    0.7251       0.05 [-0.20, 0.32], 0.637 0.003
Postoperative IABP/ECMO (% yes) 10 15 5    0.2643  -0.26 [-0.68, -0.066], 0.018 0.07
Etiology HF (%)    0.1383
Cardiomyopathy 65 56 75
Ischemic heart disease 25 34 15
Other 10 10 10
Smoking (%) no/yes/ex-smoker 49/0/51 34/0/66 65/0/35    0.0051      -0.19 [-0.34, 0.03], 0.100 0.03
24 h ambulatory blood pressure
Overall systolic BP 133 ± 12    133 ± 13 132 ± 10   0.672
Overall diastolic BP 81 ± 7    80 ± 8 82 ± 7   0.493
Medication (%)
Ciclosporin 70 63 78    0.1651
Tacrolimus 28 32 23    0.3521
Everolimus 34 43 25    0.0981
Mycophenolate 90 81 100    0.0053        0.29 [0.10, 0.71], 0.009 0.08
Prednisolone 100 100 100
Beta-blocker 28 40 15    0.0121    -0.19 [-0.39, -0.03], 0.086 0.04
Calcium blocker 25 25 25    1.0001
ACE inhibitors 3 3 3    1.0003
AII-blocker 9 13 5    0.2633
Diuretics 79 80 78    0.7851
Statins 99 98 100    1.0003
Blood samples 
TG (mmol/L) 1.7 (1.3, 2.5) 2.1 (1.5, 2.8) 1.5 (1.1, 2.2)    0.0132  -0.24 [-0,19, -0.002], 0.045 0.06
LDL (mmol/L)   2.9 ± 1.0      3.0 ± 1.2   2.9 ± 0.7   0.416       0.12 [-0.05, 0.15], 0.308 0.01
HDL (mmol/L)   1.5 ± 0.5      1.5 ± 0.5   1.6 ± 0.5   0.432       0.04 [-0.16, 0.22], 0.755 0.001
Cholesterol (mmol/L)   5.1 ± 1.3      5.3 ± 1.5   5.0 ± 1.0   0.329       0.03 [-0.07, 0.09], 0.830 0.001
Hemoglobin (g/dL) 11.8 ± 1.7    11.3 ± 1.9 12.2 ± 1.4   0.017      0.38 [0.042, 0.15], 0.001 0.14
hs-CRP (mg/L) 2.3 (1.0, 6.1) 2.7 (1.3, 6.7) 1.6 (0.6, 3.9)    0.0522 -0.17 [-0.015, 0.002], 0.125 0.03
NT-proBNP (ng/L) 968.3
(625.8, 1680.8)
1348.9 
(765.4,2006.4)
790.7
(522.2, 1351.0)
   0.0052 -0.36[-2.7E-4, -6.5-5], 0.002 0.13
hs-TnT (ng/L) 32.5 (20.0, 61.8) 42.0 (27.8, 66.7) 24.0 (18.0, 50.8)    0.0092 -0.18 [-0.005, 0.001], 0.128 0.03
HbA1c (%)   5.6 ± 0.8      5.8 ± 0.9   5.4 ± 0.7   0.038     -0.15 [-0.19, 0.04], 0.213 0.02
Glucose (mmol/L)   5.9 ± 1.8      6.3 ± 2.1   5.5 ± 1.4   0.046       -0.19 [-0.1, 0.01], 0.109 0.04
Leukocytes (× 10-9/L)   5.4 ± 2.3      6.0 ± 2.7   4.7 ± 1.6   0.017     -0.06 [-0.05, 0.03], 0.580 0.004
Creatinine (μmol/L)  117.4 ±  31.4    118.0 ± 31.9 116.9 ± 31.3   0.868 -0.05 [-0.004, 0.002], 0.669 0.002
Carbamide (mmol/L)   9.8 ± 3.4      9.9 ± 4.0   9.7 ± 2.7   0.865   -0.003 [-0.03, 0.03], 0.977 1.00E-05
eGFR (mL/min per 1.73 m2)   55 ± 16      54.1 ± 17.0   56.1 ± 15.0   0.586     0.23 [3.9E-5,0.01], 0.049 0.05
Muscle strength and muscular exercise capacity
Muscle strength (Nm)   279 ± 129      231 ± 128   326 ± 113   0.001        0.66 [0.002, 0.003], < 0.001 0.43
Muscular Exercise capacity (J)   3229 ± 1660      2423 ± 1351   4015 ± 1567 < 0.001    0.64 [0.0001, 0.0002], < 0.001 0.41
Spirometry
FEV1 (%)   81 ± 16      74 ± 14   88 ± 16 < 0.001      0.39 [0.004, 0.02], 0.001 0.16
PEF (%)   85 ± 22      79 ± 23   91 ± 20   0.018      0.37 [0.003, 0.01], 0.001 0.14
FVC (%)   86 ± 17      81 ± 16   90 ± 16   0.026     0.17 [-0.002, 0.01], 0.152 0.03
Echocardiography 
EF (%) 57.9 ± 5.6    56.2 ± 5.4 59.4 ± 5.4   0.011      0.26 [0.003, 0.04], 0.025 0.07
LVEDD (cm)   4.9 ± 0.5      4.9 ± 0.5   4.9 ± 0.4   0.996           0.42 [0.19, 0.59], < 0.001 0.18
FS (%) 36.7 ± 5.9    35.9 ± 6.8 37.5 ± 4.9   0.242   0.23 [-4.7E-5, 0.03], 0.051 0.05
CO (L/min)   6.1 ± 1.2      6.0 ± 1.2   6.2 ± 1.2   0.467        0.39 [0.06, 0.21], 0.001 0.15
Table 1  Clinical characteristics and health-related quality of life of the study population
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In addition to the main predictors mentioned above, 
self­reported physical function was also positively asso­
ciated with VO2peak in this cohort, which is in accordance 
with an earlier paper from our research team[15]. Similar 
findings are reported from the general population in the 
Norwegian HUNT study, in which physical activity level 
2N = 63-81 Total Low-capacity group
VO2peak ≤ 19.4 mL/kg 
per min (n  = 41)
High-capacity group
VO2peak > 19.4 mL/kg 
per min (n  = 40)
 t 
(P -value)
Univariate regression
Standardized coefficient 
Beta [95%CI], P  
VO2peak L/min
3R2
VO2peak (mL/kg per min) 20.4 ± 4.9 16.4 ± 2    24.3 ± 3.6 < 0.001           0.75 [0.05, 0.08], < 0.001   0.56
VO2peak (L/min)   1.6 ± 0.4      1.3 ± 0.3      1.8 ± 0.4 < 0.001
%expected VO2peak   55.8 ± 12.4    46.5 ± 7.4    65.3 ± 8.6 < 0.001           0.60 [0.01, 0.03], < 0.001   0.36
RER   1.2 ± 0.1        1.2 ± 0.14        1.2 ± 0.10   0.898
HRrest (echocardiography)   87 ± 10      87 ± 11    86 ± 9 0.85 -0.07 [-0.013, 0.007], 0.551   0.01
Peak systolic BP (mmHg) 188 ± 30    188 ± 31    189 ± 30   0.865  0.19 [-0.001, 0.006], 0.108   0.04
Peak diastolic BP (mmHg)   82 ± 17      82 ± 18      82 ± 16   0.917  0.09 [-0.004, 0.008], 0.467   0.01
VE/VCO2slope 34.8 ± 7.7    37.3 ± 7.2    32.6 ± 7.6   0.008     -0.42 [-0.035, -0.01], < 0.001   0.18
Vmax (L)   71.4 ± 22.8      60.5 ± 17.5      81.7 ± 22.7 < 0.001            0.76[0.01, 0.02], < 0.001   0.58
O2 pulse (mL/beat) 12.4 ± 3.3 11.0 ± 3 13.7 ± 3 < 0.001           0.80 [0.08, 0.12], < 0.001   0.65
AT (L/min) 1.08 ± 0.3    0.95 ± 0.2      1.2 ± 0.3   0.001             0.73 [0.74, 1.2], < 0.001   0.53
METS   6.5 ± 1.6      5.4 ± 0.8      7.8 ± 1.3 < 0.001           0.77 [0.16, 0.24], < 0.001   0.59
HRpeak (beats/min) 128 ± 19    121 ± 19    134 ± 17   0.001     0.31 [0.002, 0.01], 0.005 0.1
%HRmax   75 ± 12      72 ± 12      78 ± 11   0.021    0.20 [-0.001, 0.02], 0.071   0.04
HRreserve (beats/min)   43 ± 16      35 ± 13      50 ± 15 < 0.001           0.47 [0.01, 0.02], < 0.001   0.22
CRI 0.51 ± 0.2      0.45 ± 0.18    0.57 ± 0.2   0.004        0.31 [0.20, 1.12], 0.005 0.1
RPE (Borg scale) 18.6 ± 0.8 18.5 ± 1    18.6 ± 0.5   0.638
Test duration (min)   9.5 ± 2.8      7.8 ± 1.5    11.1 ± 2.7 < 0.001
HRrecovery
Beats /min at 2 min -1.0 (-3.0, 1.0) -1.0 (-3.0, 1.0) -2.0 (-3.3, 1.3)     0.6971
Table 2  Cardiopulmonary responses to exercise of the study population
Groups are divided according to the median VO2peak (mL/kg per min). Variables are presented as mean ± SD or as median (Q1, Q3) where appropriate. 
1Mann Whitney U-test; 2The actual N varies from 63 to 81 for different variables; 3Unadjusted R2. BP: Blood pressure; CI, confidence interval; CRI, 
chronotropic response index; HR, heart rate; METS, metabolic equivalents; Vmax, maximum ventilation; Q1, first quartile; Q3, third quartile; RER, 
Respiratory Exchange Ratio; RPE, rated perceived exertion; SD, standard deviation. 
Health-related quality of life 
PCS 43 ± 8    41 ± 7 45 ± 8   0.029      0.35 [0.008, 0.03], 0.001 0.13
MCS   54 ± 11      53 ± 10   55 ± 11   0.416     0.17 [-0.002, 0.02], 0.127 0.03
Symptoms of anxiety and depression
HADS-A ≥ 8 (%)4                   15 17 13    0.5621  -0.26 [-0.56, -0.05], 0.02 0.07
HADS-D ≥ 8 (%)5 5 5 5    1.0003     -0.16 [-0.73, 0.13], 0.165 0.03
Groups are divided according to the median VO2peak (mL/kg per min). Variables are presented as percentages, mean ± SD or as median (Q1, Q3) where 
appropriate. 1χ 2; 2Mann Whitney U-test; 3F; 4HADS-A score ≥ 8 indicates symptoms of anxiety; 5HADS-D score ≥ 8 indicates symptoms of depression; 6The 
actual N varies from 55 to 81 for different variables; 7Unadjusted R2. ACE: Angiotensin-converting enzyme; ATII: Angiotensin Ⅱ; BP: Blood pressure; CO: 
Cardiac output; ECMO: Extracorporeal membrane oxygenation; EF: Ejection fraction; FEV1: Forced expiratory volume at 1 min; FVC: Forced vital capacity; 
FS: Fractional shortening; HADS: Hospital anxiety and depression scale; HbA1c: Hemoglobin A1c; HDL: High density lipoprotein; hs-CR: High-sensitive 
C-reactive protein; hs-TnT: High-sensitive troponin T; HTx: Heart transplantation; IABP: Intra-aortic balloon pump; LVAD: Left ventricle assist device; 
LVEDD: Left ventricular end diastolic diameter; MCS: Mental component summary; Nm: Newton meter; NT-pro BNP: N-terminal pro brain natriuretic 
peptide; PEF: Peak expiratory flow; PCS: Physical component summary; Q1: First quartile; Q3: Third quartile; SD: Standard deviation; TG: Triglyceride.
N = 66 Model 1 
Standardized coefficient Beta [95% CI]
P -value Model 2 
Standardized coefficient Beta [95% CI] 
P -value
O2 pulse (mL/beat) 0.707 [0.075, 0.104] < 0.001     0.675 [0.069, 0.102] < 0.001
HRreserve (beats/min) 0.382 [0.007, 0.013] < 0.001     0.397 [0.008, 0.013] < 0.001
Muscular exercise capacity (Joule)    0.162 [1.1E-5, 7.1E-5] 0.008 0.155 [8.0-5, 7.1-5] 0.015
BMI (kg/m2)      0.067 [-0.004, 0.020] 0.211
Sex     -0.029 [-0.142, 0.086] 0.630
Age (yr)      0.019 [-0.003, 0.004] 0.719
Adjusted R2 0.85 0.84
Table 3  Multiple regression analysis
Dependent variable VO2peak L/min. Final model for n = 66. BMI: Body mass index; CI: Confidence interval; HR: Heart rate. 
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in our current study had a lower score on the physical 
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function subscale compared to the norm values described 
in Ware et al[25], the high­capacity group had a clinical 
meaningful and significantly higher score than the low-
capacity group on physical function. The high­capacity 
group also had higher score on the PCS. On the other 
hand, there were no differences between the two groups 
regarding the psychosocial subscales or MCS in SF­36v2.
As previously mentioned, only two previous studies 
exist that describe determinants for VO2peak in de novo 
HTx recipients[6,12]. Kitagaki et al[6] found that knee 
extensor muscle strength and cholinesterase were 
important predictors for VO2peak 55 d after surgery. Salyer 
et al[12] found that age was the only predictor of VO2 peak 
68 d after HTx, but they did not include muscular exercise 
capacity or chronotropic variables in their regression 
analyses. A small study (n = 15) by Oliveira Carvalho 
et al[30] described that HRreserve, as the only important 
variable, was associated with VO2peak six months after 
HTx, while in maintenance HTx recipients, HRreserve was no 
longer strongly  associated with VO2peak. In HRrecovery after 
exercise, there was an important difference between 
early and late HTx recipients, suggesting a partial 
reinnervation in maintenance HTx recipients[30]. However, 
peripheral factors such as muscular exercise capacity 
were not measured in Oliveira Carvalho’s study[30]. Borelli 
et al[31] followed HTx recipients for two years and found 
that both central and peripheral factors contributed to the 
reduced VO2peak both early (5.3 mo) and late (2 years) 
after HTx, but that the improvements in VO2peak seen 
over two years were mostly related to peripheral factors. 
In the present study, both HRreserve and O2 pulse were 
independent predictors of VO2peak. The chronotropic re­
sponses, CRI, %HRmax and HRpeak were, as expected, 
lower than normal both in the low­capacity and the high­
capacity group. However, the high­capacity group had 
better chronotropic responses than the low­capacity 
group (CRI, P = 0.004; %HRmax, P = 0.021, HRpeak, P 
= 0.001; HRreserve, P < 0.001). HRrecovery was markedly 
delayed in both groups, with no difference between the 
groups. Previous studies in maintenance HTx recipients 
have reported conflicting results whether chronotropic 
incompetence is associated with a reduced VO2peak or 
not. Schwaiblmair et al[32] and Kemp et al[33] found a 
higher VO2peak in patients with a greater HRreserve, com­
pared to patients with a lower HRreserve. In contrast, 
Squires et al[34] found no difference in VO2peak between 
patients with high versus low HRreserve (46 ± 15 vs 33 ± 
15). In a previous study by our research group, where 
maintenance HTx recipients demonstrated a close to 
normal chronotropic response, HRreserve was not a strong 
determinant of VO2peak[20]. However, in this current study 
of de novo HTx recipients, it is (Figure 1). The findings 
described above suggest that as the initially impaired 
chronotropic responses improve over time, they become 
less predictive of VO2peak.
O2 pulse derived from CPET is considered a surrogate 
for stroke volume[14,35,36]. In the current study, there was 
a strong correlation between VO2 peak and O2 pulse (Figure 
2). In line with this, the high­capacity group also had a 
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Figure 1  Scatterplot of the correlation between peak oxygen consumption 
(L/min) and heart rate reserve with inserted regression line. R2 = 0.224. 
Pearsons r 0.473, P < 0.001. VO2peak: Peak oxygen consumption; HRreserve: Heart 
rate reserve.
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Figure 2  Scatterplot of the correlation between peak oxygen consumption 
(L/min) and O2 pulse with inserted regression line. R2 = 0.647. Pearsons r 
0.804, P < 0.001. VO2peak: Peak oxygen consumption.
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higher O2 pulse (P < 0.001), increased left ventricular EF, 
as well as lower NT-proBNP and hs-TnT levels, reflecting 
a better preserved myocardial function compared with 
the low­capacity group.
De novo HTx recipients have reduced muscle mass 
mostly due to inactivity prior to HTx[18]. The high­capacity 
group had higher muscular exercise capacity (P < 0.001) 
and muscular strength (P = 0.001) than the low­capacity 
group (Figure 3), and this finding supports the previously 
described association between muscle function and 
VO2peak[20]. Comparing the muscle strength values from 
our previous study on maintenance recipients[20] with 
the values in this current study, they are not surprisingly 
much lower in the de novo recipients. As muscular 
exercise capacity is the only peripheral predictor for VO2 
peak in the current study, peripheral factors might be less 
dominant than central factors in the early phase after 
HTx. However, from a clinical point of view, resistance 
training in the early rehabilitation after HTx is of high 
importance in order to prevent and restore loss of muscle 
mass and bone density and is likely to contribute to an 
improved VO2peak level[37]. 
In the existing literature, VO2peak in de novo HTx 
patients is reported to range from 9.2 mL/kg per min up 
to 19.7 mL/kg per min (1­3 mo after HTx)[2­12]. One small 
study of nine patients with left ventricle assist device 
(LVAD) prior to HTx had a mean VO2peak of 24.6 mL/kg 
per min 12 wk after HTx, which is higher than what has 
been reported in other studies and may be explained by 
the LVAD effect and the patients’ relatively high VO2peak 
before HTx[38]. Except for this study, our cohort’s mean 
VO2peak level of 20.4 mL/kg per min (measured 11 wk 
post HTx) is higher than what is previously reported in 
de novo HTx recipients. Compared to an earlier exercise 
study in maintenance HTx recipients from our center with 
a median VO2peak  value of 27.3 mL/kg per min[20], this 
de novo HTx cohort is below this value, but compared to 
other international studies in maintenance HTx recipients, 
our current de novo HTx recipients are close to these 
reported values[18]. This may be partially related to the 
early and individualized exercise program conducted at 
our centers, where the patients are attended to daily by 
a physical therapist from the multidisciplinary HTx team. 
Results from a CPET test can be important in many 
aspects in the early phase after HTx. First of all, a 
maximal exercise test is of great value to the individual 
patient in terms of contributing to increased confidence in 
their new heart and the body’s tolerance to high­intensity 
exercise. Secondly, an early CPET is useful for deciding 
and tailoring the individual exercise programs and for 
the further rehabilitation, both for monitoring patients’ 
status and prognosis and measuring effect of exercise. In 
addition to the many gas exchange variables, the CPET 
also provides other valuable and useful measurements, 
such as lung function and chronotropic responses. 
Finally, as we know that measures of physical capacity 
are strong predictors for long­term survival in HTx 
recipients[15,16], we suggest that such measures should 
be routinely included both in the early phase after HTx 
and at yearly controls thereafter. We underscore that the 
safety aspect is very important when performing a CPET 
and it should always be supervised by competent and 
experienced health personnel.
Limitations
Selection bias is a common risk in all voluntary studies, 
and although our aim was to include every newly trans­
planted HTx recipient, the recipients had to be medically 
stable and able to perform a maximal CPET and other 
physical tests. Thus, as the median VO2peak value in 
this de novo cohort is comparable to maintenance HTx 
recipients’ VO2peak values, this may be due to a possible 
selection bias.
This is a cross­sectional study, based on the baseline 
data from an ongoing RCT, and no causal relationships 
should be drawn from such a study design. We present 
only associations between VO2peak and different possible 
determinants. A rather small sample size (n = 81) may 
also imply type 2 errors, but all the performed statistics 
were carefully checked for underlying assumptions.
In this de novo HTx cohort, the age­predicted mean 
VO2 peak value was 56% of age­expected values, which is 
comparable to previously reported values in maintenance 
HTx[18]. Predictors for VO2peak in de novo HTx recipients 
seem to be of both central (O2 pulse and HRreserve) 
and peripheral (muscular exercise capacity) origin. A 
CPET and determination of muscular exercise capacity 
provide important information for patient motivation, 
rehabilitation and prognosis and thus, measurements 
for physical function should be considered as routine 
examinations early after HTx.
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ARTICLE HIGHLIGHTS
Research background 
Peak oxygen consumption (VO2peak) is reduced after heart transplant (HTx). 
Both peripheral and central factors are determinants of the reduced VO2peak 
in maintenance HTx recipients, but there are still few studies among de novo 
HTx patients. A higher VO2peak is associated with better prognosis after HTx, 
and knowledge about predictors for VO2peak in de novo HTx is important for the 
rehabilitation process.  A cardiopulmonary exercise test (CPET) is the gold 
standard for measuring VO2peak and should be performed as a routine test early 
after HTx. 
Research motivation
More knowledge about predictors for VO2peak in de novo HTx patients may 
contribute to a better understanding of the reduced exercise capacity early after 
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HTx. Individualized exercise prescriptions are very important after HTx, and 
a CPET early after HTx will guide both clinicians and physiotherapists in this 
vulnerable phase of the rehabilitation process. 
Research objectives
The aim of this study was to investigate determinants of early VO2peak and 
exercise capacity in a cohort of de novo HTx recipients.
Research methods
This study used baseline data from an ongoing randomized controlled trial 
investigating high-intensity interval training compared to moderate continuous 
exercise training among de novo HTx recipients, the HITTS study. A cross 
sectional analysis was performed on the baseline data from the 81 patients 
included in the study, and all baseline tests were performed an average of 11 wk 
after surgery. The primary endpoint was VO2peak measured by CPET. Secondary 
endpoints were lung function, maximum muscle strength and muscular exercise 
capacity, bioelectrical impedance analysis, echocardiography, blood samples 
and health-related quality of life. 
Research results
The main findings in this study were that de novo HTx patients display reduced 
exercise capacity compared to a general population, but comparable with 
maintenance HTx recipients. This de novo HTx cohort demonstrated a median 
VO2peak level of 19.4 mL/kg per min at 11 ± 1.8 wk post-HTx. Maximal exercise 
capacity was determined by both central (O2 pulse and HRreserve) and peripheral 
factors (muscular exercise capacity). The CPET tests were performed without 
any serious adverse events mean 11 wk after HTx. This is a cross-sectional 
study, and no causal relationships should be drawn from such a study 
design. We present only associations between VO2peak and different possible 
determinants.  
Research conclusions
In this de novo HTx cohort, the age-predicted mean VO2 peak value was 56% 
of age-expected values, which is comparable to previously reported values in 
maintenance HTx. Predictors for VO2peak in de novo HTx recipients seem to be 
of both central and peripheral origin. 
Research perspectives
A CPET and determination of muscular exercise capacity provide important 
information for patient motivation, rehabilitation and prognosis and thus, 
measurements for physical function should be considered as routine 
examinations early after HTx.
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